NAGOYA, Japan--(BUSINESS WIRE)--Cytori (NASDAQ: CYTX) announced that the first patient was enrolled in an investigator-initiated safety and feasibility study using adipose-derived stem and regenerative cells to treat stress urinary incontinence. The 10-patient study is being conducted independently by Nagoya University Hospital in Japan. Cytori's Celution® 800 System is being used to process and extract the patients' own adipose tissue-derived stem and regenerative cells at the time of surgery.
